A Phase II, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Determine the Safety and Efficacy of a Topical Patch (AB001) Following Daily Administration for 2 Weeks in Patients With Chronic Low Back Pain

Trial Profile

A Phase II, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Determine the Safety and Efficacy of a Topical Patch (AB001) Following Daily Administration for 2 Weeks in Patients With Chronic Low Back Pain

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs AB 001 (Primary)
  • Indications Back pain
  • Focus Therapeutic Use
  • Sponsors Frontier Biotechnologies
  • Most Recent Events

    • 22 Jun 2016 Primary endpoint has been met. (Change of Pain intensity on VAS on Day 15), as reported in a Frontier Biotechnologies media release.
    • 22 Jun 2016 Results published in a Frontier Biotechnologies media release.
    • 02 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top